AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00004816
Drug: monoclonal antibody M-T412
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01814683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days placebo.
Trial: NCT00048399
Drug: CAMPATH 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178293
Drug: Ketoprofen lysine salt
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00050986
Drug: R115777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
Trial: NCT01724112
Drug: LY2940094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01724112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01885078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00789269
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of placebo
Trial: NCT00377910
Drug: Aethoxysclerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Trial: NCT03665428
Drug: PAMB treatment (modified quadruple therapy)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly assign either as PAMB or PBMT group treatment
Trial: NCT03665428
Drug: PBMT treatment (bismuth-containing quadruple therapy)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly assign either as PAMB or PBMT group treatment
Trial: NCT03415763
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Trial: NCT03415763
Drug: mFOLFOX6 or CAPOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Trial: NCT03827590
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times a day for five days
Trial: NCT00722761
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (no active drug) given once daily for 24 weeks
Trial: NCT03827590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times a day for five days
Trial: NCT01471860
Drug: Medical Management
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004469
Drug: P-3074
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004469
Drug: P-3074 Vehicle
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03565445
Drug: ASP1948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously (IV)
Trial: NCT02070406
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01549743
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg will be administered orally twice a day for 3 days
Trial: NCT01549743
Drug: Celecoxib plus Rebamipide
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide
Trial: NCT01628094
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01628094
Drug: RO5190591
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01628094
Drug: RO5466731
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02207556
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use.
Trial: NCT00796133
Drug: NES/E2 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Trial: NCT02482441
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
Trial: NCT02465593
Drug: PEP503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
Trial: NCT02465593
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
Trial: NCT01389973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Trial: NCT02289391
Drug: Anesthesia induction
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
Trial: NCT02289391
Drug: Anesthesia maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.
Trial: NCT02289391
Drug: Assisted anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
Trial: NCT00786929
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03822871
Drug: CTT1403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
Trial: NCT02418533
Drug: Recominant Follicle Stimulating Hormone (rFSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonal-f is used for controlled ovarian stimulation (COH)
Trial: NCT00803543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: Two tablets once a day for 24 weeks
Trial: NCT04514159
Drug: ZN-c5
RxNorm normalized name: dipentaerythrityl hexa C5-10 acid esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c5 is the study drug.
Trial: NCT04154787
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation of LNP023
Trial: NCT00576251
Drug: Tobramycin 0.3%/Dexamethasone 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
Trial: NCT00542724
Drug: VIAject™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage as individually required
Trial: NCT00542724
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage as individually required
Trial: NCT03160105
Drug: Switch to DTG + FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from standard cART to DTG + FTC dual maintenance therapy.
Trial: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
Trial: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, with food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
Trial: NCT01327872
Drug: E5501 40mg 2 x 20-mg tablets, orally, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
Trial: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, with food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
Trial: NCT01552187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 48 to 72 hours before surgery till 1 months after surgery
Trial: NCT02498483
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants will receive 15 mg/kg of acetaminophen.
Trial: NCT04352595
Drug: Hemay808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Trial: NCT01811355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00311558
Drug: SSG & interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 arm study with SSG \& interferon
Trial: NCT01594333
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
Trial: NCT01594333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
Trial: NCT01682460
Drug: Refresh Tears Lubricant Eye Drops (Allergan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops QID for 1 month
Trial: NCT02393573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
Trial: NCT03298191
Drug: Calcium Channel Blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Those women will be given Calcium Channel Blockers for tocolysis
Trial: NCT02559154
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00463190
Drug: Biothree
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02559154
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02559154
Drug: Mitoxsnteone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01925859
Drug: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
Trial: NCT02379754
Drug: Gentamicins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Trial: NCT04684914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT04802980
Drug: HB002.1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB002.1T is a vascular endothelial growth factor receptor decoy
Trial: NCT04802980
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an anti-tumor drug
Trial: NCT00917306
Drug: PEP005 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% two day treatment
Trial: NCT03054948
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In most cases standard therapy will be IntraLipid.
Trial: NCT01887587
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01887587
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00473837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
Trial: NCT02896712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsule will be filled with corn starch and riboflavin.
Trial: NCT00694694
Drug: azithromycin + artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
Trial: NCT00694694
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days
Trial: NCT01016691
Drug: Placebo Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: device inserted for 4 days
Trial: NCT01808690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04095754
Drug: Induction and maintenance of anaesthesia
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Trial: NCT00292448
Drug: Ba 679 BR Respimat
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01021852
Drug: Dose-matched Placebo to MK-6096
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
Trial: NCT02345031
Drug: AUT00063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg, orally, once a day, for 4 weeks
Trial: NCT02345031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, once a day, for 4 weeks
Trial: NCT00138424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control for this study is sterile, 0.9% normal saline for intravenous use.
Trial: NCT02517151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01912716
Drug: high dose indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients randomized to this intervention receive 200mg indomethacin
Trial: NCT01912716
Drug: standard dose indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients randomized to this intervention receive 100mg indomethacin
Trial: NCT03280342
Drug: IR-TPM (Topamax)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-TPM (Trokendi XR)
Trial: NCT02193815
Drug: PF06263276
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
Trial: NCT00854178
Drug: Comparison of two anesthetic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
Trial: NCT00930605
Drug: CHOP regimen alternate with ESHAP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
Trial: NCT00986427
Drug: Refresh® Dry Eye therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion contains glycerin 1% and polysorbate 80
Trial: NCT00574496
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02946541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, QD
Trial: NCT01527019
Drug: Cephalosporins
RxNorm normalized name: First-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Trial: NCT01527019
Drug: Cephalosporins
RxNorm normalized name: First-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Trial: NCT01881971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suger pill manufactured to mimic crestor pills
Trial: NCT01881971
Drug: Rouvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01367873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, matching number of placebo capsule(s) with active arm
Trial: NCT03329651
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Trial: NCT00406783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily for 15 days
Trial: NCT00450801
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
Trial: NCT00450801
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
Trial: NCT00064350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
Trial: NCT04396834
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet (BID)
Trial: NCT03902782
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described earlier
Trial: NCT03902782
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described earlier
Trial: NCT00450801
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
Trial: NCT00450801
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
Trial: NCT02947126
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 7% Hypertonic saline
Trial: NCT02947126
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 0.9% Isotonic saline
Trial: NCT01089426
Drug: Omegaven™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg/d of Omegaven until discontinuation of PN
Trial: NCT02242474
Drug: Anti-TNF suspended perioperatively
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242474
Drug: Anti-TNFα continued perioperatively
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05412472
Drug: GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg IV infusion of GC4419 over 60 minutes.
Trial: NCT00958269
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no